Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma

摘要: // Pavlos Msaouel 1, * , Amado J. Zurita Shixia Huang 2 Eric Jonasch 1 and Nizar M. Tannir Department of Genitourinary Medical Oncology, The University Texas M.D. Anderson Cancer Center, Houston, TX, USA Dan L. Duncan Center & Molecular Cellular Biology Alkek for Discovery, Baylor College Medicine, These authors have contributed equally to this work Correspondence to: Tannir, email: ntannir@mdanderson.org Keywords: biomarkers, cytokines angiogenic factors, everolimus, non-clear cell renal carcinoma, sunitinib Received: September 20, 2016     Accepted: January 16, 2017     Published: February 02, 2017 ABSTRACT No biomarkers are available predict relative clinical benefit from targeted therapies in patients with carcinoma (nccRCC). To identify candidate predictive markers, we investigated a set factors (CAFs) previously untreated nccRCC participating the phase II ESPN trial comparing first-line everolimus. Pre-treatment concentrations 30 CAFs were measured plasma 37 treated everolimus (n=16) or (n=21), associated progression-free (PFS) overall survival (OS) after adjusting potential confounders. High (>median) soluble glycoprotein 130 (sgp130) longer PFS compared (HR = 0.30; 95% CI: 0.11-0.85; P 0.024). Significantly shorter was noted, independently treatment arm, high levels IL-8 3.13; 1.41-6.92), IL-13 3.36; 1.49-7.58), tumor necrosis factor receptor 2.21; 1.04-4.72). also significantly OS 3.55; 1.55-8.14). Thus, using CAF profiling identified prognostic circulating that can be used inform therapeutic decisions nccRCC.